Archive — US — techcrunch
Serena-backed health tech lands first FDA approval for home cervical cancer test
Teal Health's Teal Wand, the first FDA-approved home cervical cancer test, allows patients to self-collect samples for analysis, improving accessibility to essential screenings. Backed by Serena Ventures and others, the device aims to alleviate the intimidation associated with traditional pap smears. The initial release starts in California in June 2023.
Key points
- The FDA has approved a home cervical cancer test called Teal Wand from Teal Health.
- Teal Wand allows users to self-collect samples for cervical cancer screening and mail them to a lab.
- The device aims to make cervical cancer screenings less intimidating for women.
- Teal Health received a $10 million seed extension round, bringing total funding to $23 million.
- Investors include Serena Ventures, Chelsea Clinton, Emerson Collective, and Forerunner.
- One in four women are currently overdue for cervical cancer screenings, highlighting the need for improved access.
- The Teal Wand Kit includes a collection device and virtual access to medical providers for result reviews.
- The product will initially launch in California in June 2023.
Why it matters
- The shift towards at-home medical testing reflects broader trends in healthcare technology emphasizing accessibility.
- Similar innovations have emerged in other areas of health tech, driven by the COVID-19 pandemic's impact on telehealth.
- Monitoring cervical cancer has historical importance as it was previously one of the leading cancers in women, now reduced through effective screenings.
- In 2025, healthcare trends show an increased focus on personalized medicine and remote patient monitoring.
The FDA's approval of the Teal Wand represents a significant advance in women's health, enhancing access to crucial cervical cancer screenings while reflecting continued trends towards home-based healthcare solutions.